208 related articles for article (PubMed ID: 32036793)
41. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
42. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
43. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia.
Sathienluckana T; Jansing T; Srisuriyakamon S; Thonkhunthod A; Sangsuwanto P; Losatiankij P; Supanya S
Ann Pharmacother; 2024 Jun; 58(6):598-604. PubMed ID: 37743679
[TBL] [Abstract][Full Text] [Related]
45. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
46. Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions.
De Leon J; Sanz EJ; De Las Cuevas C
Schizophr Bull; 2020 Jan; 46(1):1-3. PubMed ID: 31901099
[No Abstract] [Full Text] [Related]
47. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
48. Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.
Garriga M; Mallorquí A; Bernad S; Ruiz-Cortes V; Oliveira C; Amoretti S; Mezquida G; Bioque M; Molina O; Gómez-Ramiro M; Vieta E; Bernardo M; Parellada E; García-Rizo C
J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):75-80. PubMed ID: 34928563
[TBL] [Abstract][Full Text] [Related]
49. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
50. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study.
Hung GC; Liu HC; Yang SY; Pan CH; Liao YT; Chen CC; Kuo CJ
J Clin Psychiatry; 2016 Jan; 77(1):60-6. PubMed ID: 26613551
[TBL] [Abstract][Full Text] [Related]
51. Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database.
Hatano M; Yamada K; Matsuzaki H; Yokoi R; Saito T; Yamada S
PLoS One; 2023; 18(6):e0287122. PubMed ID: 37307250
[TBL] [Abstract][Full Text] [Related]
52. Infections associated with clozapine: a pharmacovigilance study using VigiBase
Chrétien B; Brazo P; Da Silva A; Sassier M; Dolladille C; Lelong-Boulouard V; Alexandre J; Fedrizzi S
Front Pharmacol; 2023; 14():1260915. PubMed ID: 37849735
[No Abstract] [Full Text] [Related]
53. [Intensive pharmacovigilance of clozapine in Argentina].
Balda MV; Daray FM
Vertex; 2015; 26(122):292-301. PubMed ID: 26672506
[TBL] [Abstract][Full Text] [Related]
54. Risk of appendicitis associated with the use of clozapine: A pharmacovigilance study.
Uwai Y; Nabekura T
Asian J Psychiatr; 2022 Nov; 77():103264. PubMed ID: 36150349
[No Abstract] [Full Text] [Related]
55. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
56. Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report.
Barros FMR; Tolentino AC; Marques LSK; Schlittler LXC; Oliveira KD; Dalgalarrondo P; Barnes LL; Dos Santos Junior A; Banzato CEM
Schizophr Bull; 2024 Apr; 50(3):717-719. PubMed ID: 38502910
[TBL] [Abstract][Full Text] [Related]
57. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.
Sumiyoshi T; Roy A; Anil AE; Jayathilake K; Ertugrul A; Meltzer HY
J Clin Psychopharmacol; 2004 Jun; 24(3):345-8. PubMed ID: 15118492
[No Abstract] [Full Text] [Related]
58. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
59. Prolongation of clozapine-induced leukopenia with olanzapine treatment.
Sayin A; Cosar B
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):958-9. PubMed ID: 16631295
[TBL] [Abstract][Full Text] [Related]
60. Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study.
Druschky K; Toto S; Bleich S; Baumgärtner J; Engel RR; Grohmann R; Maier HB; Neyazi A; Rudolph YJ; Rüther E; Schwörer H; Seifert J; Stübner S; Degner D
World J Biol Psychiatry; 2021 Jun; 22(5):373-386. PubMed ID: 32892689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
